FERRARI, Roberto
 Distribuzione geografica
Continente #
NA - Nord America 39.207
EU - Europa 10.518
AS - Asia 7.398
SA - Sud America 130
AF - Africa 39
OC - Oceania 30
Continente sconosciuto - Info sul continente non disponibili 14
Totale 57.336
Nazione #
US - Stati Uniti d'America 39.096
CN - Cina 3.606
IT - Italia 3.170
UA - Ucraina 2.394
SG - Singapore 1.687
TR - Turchia 1.443
DE - Germania 1.362
GB - Regno Unito 1.038
SE - Svezia 697
FI - Finlandia 598
PL - Polonia 488
ID - Indonesia 221
FR - Francia 217
VN - Vietnam 140
BE - Belgio 114
CA - Canada 87
BR - Brasile 75
IN - India 69
NL - Olanda 65
RU - Federazione Russa 62
CZ - Repubblica Ceca 50
ES - Italia 46
HK - Hong Kong 42
CH - Svizzera 32
LT - Lituania 31
IE - Irlanda 24
KR - Corea 23
CO - Colombia 21
AU - Australia 20
IQ - Iraq 17
IR - Iran 17
RO - Romania 17
LK - Sri Lanka 16
EG - Egitto 14
JP - Giappone 14
PK - Pakistan 14
EU - Europa 12
HR - Croazia 12
MX - Messico 12
AL - Albania 11
HU - Ungheria 11
IL - Israele 10
NZ - Nuova Zelanda 10
PT - Portogallo 10
TW - Taiwan 10
CL - Cile 9
TH - Thailandia 9
BG - Bulgaria 8
DK - Danimarca 8
EC - Ecuador 8
GE - Georgia 8
GR - Grecia 8
NO - Norvegia 8
RS - Serbia 8
SA - Arabia Saudita 8
AT - Austria 7
AR - Argentina 6
PE - Perù 6
PH - Filippine 6
ZA - Sudafrica 6
MY - Malesia 5
SK - Slovacchia (Repubblica Slovacca) 5
MK - Macedonia 4
SI - Slovenia 4
TN - Tunisia 4
YE - Yemen 4
BO - Bolivia 3
CU - Cuba 3
MD - Moldavia 3
MV - Maldive 3
AE - Emirati Arabi Uniti 2
AM - Armenia 2
AZ - Azerbaigian 2
BD - Bangladesh 2
CM - Camerun 2
CY - Cipro 2
ET - Etiopia 2
GH - Ghana 2
JO - Giordania 2
KG - Kirghizistan 2
KW - Kuwait 2
KZ - Kazakistan 2
LU - Lussemburgo 2
MA - Marocco 2
NI - Nicaragua 2
PA - Panama 2
SN - Senegal 2
SV - El Salvador 2
UG - Uganda 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AF - Afghanistan, Repubblica islamica di 1
AP - ???statistics.table.value.countryCode.AP??? 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CR - Costa Rica 1
EE - Estonia 1
GL - Groenlandia 1
HN - Honduras 1
KE - Kenya 1
Totale 57.325
Città #
Fairfield 5.337
Woodbridge 5.000
Houston 3.146
Jacksonville 2.703
Ashburn 2.657
Chandler 2.389
Ann Arbor 2.106
Seattle 2.089
Wilmington 1.864
Cambridge 1.776
Santa Clara 1.614
Singapore 1.293
Izmir 952
Nanjing 869
Princeton 751
Beijing 564
San Diego 477
Warsaw 471
Boardman 406
Milan 332
Ferrara 314
Shenyang 260
Shanghai 253
Nanchang 244
New York 231
Jakarta 210
Los Angeles 171
Falls Church 155
Hebei 147
Changsha 145
Jiaxing 143
Rome 141
Bremen 134
Redwood City 132
Tianjin 131
London 121
San Mateo 121
Mountain View 119
Dong Ket 118
Brussels 110
Addison 107
Helsinki 99
Jinan 97
Zhengzhou 83
Norwalk 82
Dearborn 80
Ningbo 65
Kunming 62
Naples 62
Washington 59
Bologna 54
Des Moines 53
Guangzhou 51
Orange 51
Verona 51
Munich 48
Philadelphia 48
Taizhou 45
Napoli 43
Indiana 38
Chicago 36
Tappahannock 35
Turin 32
Hong Kong 30
Ottawa 30
Auburn Hills 28
Florence 28
Hangzhou 27
Redmond 27
Frankfurt am Main 25
Changchun 24
Brno 23
Kilburn 23
Toronto 23
Lanzhou 22
Padova 22
Bari 21
Augusta 18
Palermo 18
Hounslow 17
Leawood 17
Olomouc 17
Catania 16
Torino 16
Genova 14
Pisa 14
San Francisco 14
Dublin 13
Falkenstein 12
Mumbai 12
Wuhan 12
Yellow Springs 12
Cagliari 11
Haikou 11
Hefei 11
Monmouth Junction 11
Brescia 10
Hamburg 10
Lappeenranta 10
Montréal 10
Totale 42.236
Nome #
IL METABOLISMO DEL MIOCARDIO ISCHEMICO IBERNATO E STORDITO: DIFFERENZA TRA NECROSI E APOPTOSI 1.713
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD 328
Il lungo cammino degli inibitori dell'enzima di conversione dell'angiotensina nella lotta per le malattie cardiovascolari 272
Physical activity intervention for elderly patients with reduced physical performance after acute coronary syndrome (HULK study): Rationale and design of a randomized clinical trial 267
Valutazione ecocardiografica dell'insufficienza mitralica nella prospettiva della riparazione valvolare 243
Scompenso cardiaco con frazione di eiezione intermedia. Alla ricerca della Terra di Mezzo? 223
The Notch pathway: a novel therapeutic target for cardiovascular diseases? 218
Left ventricular ejection fraction and heart failure: an indissoluble marriage? 211
null 206
Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease 198
Demographic and clinical characteristics of patients with stable coronary artery disease: results from the CLARIFY registry in Spain 196
Estrogen receptor β-dependent Notch1 activation protects vascular endothelium against tumor necrosis factor α (TNFα)-induced apoptosis 196
1,3,8-Triazaspiro compounds and their use as medicaments for the treatment of reperfusion injury. 196
Distinct gene expression profiles associated with Notch ligands Delta-like 4 and Jagged1 in plaque material from peripheral artery disease patients: A pilot study 193
Polar plot maps by parametric strain echocardiography allow accurate evaluation of non-viable transmural scar tissue in ischaemic heart disease 170
Fo ATP synthase C subunit serum levels in patients with ST-segment Elevation Myocardial Infarction: Preliminary findings 169
Mitochondrial permeability transition involves dissociation of F1FO ATP synthase dimers and C-ring conformation 168
New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma 165
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) 164
Effects of temperature on myocardial calcium homeostasis and mitochondrial function during ischemia and reperfusion. 159
17β-Estradiol Enhances Signalling Mediated by VEGF-A-Delta-Like Ligand 4-Notch1 Axis in Human Endothelial Cells 159
Heart failure with preserved ejection fraction: uncertainties and dilemmas 155
The role of Notch pathway in cardiovascular diseases. 155
Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profile 153
2014 ESC guidelines on the diagnosis and treatment of aortic diseases 153
Factor XI rs2036914 gene polymorphism and occurrence of adverse events after percutaneous coronary intervention. A prospective evaluation. 152
Cardiac resynchronization therapy guided by multimodality cardiac imaging 152
Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL 151
CANCER THERAPY-INDUCED CARDIOTOXICITY: ROLE OF ULTRASOUND DEFORMATION IMAGING AS AN AID TO EARLY DIAGNOSIS 151
CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure 151
Reversibility of Left Ventricle Longitudinal Strain Alterations Induced by Adjuvant Therapy in Early Breast Cancer Patients 151
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy 148
Kounis-Zavras syndrome presenting with ventricular arrhythmias and cardiogenic shock 147
Poor response to clopidogrel: current and future options for its management 147
The frailty in elderly patients receiving cardiac interventional procedures (FRASER) program: rational and design of a multicenter prospective study 146
The role of notch in the cardiovascular system: potential adverse effects of investigational notch inhibitors 146
Tissue factor and coagulation factor VII levels during acute myocardial infarction: association with genotype and adverse events. 145
Uric acid and coronary artery disease: An elusive link deserving further attention 143
Short Physical Performance Battery and all-cause mortality: Systematic review and meta-analysis 142
Inhaled corticosteroid/long-acting bronchodilator treatment mitigates STEMI clinical presentation in COPD patients 142
EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT) 142
Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease: Systematic review and meta-analysis 141
Discovery of Novel 1,3,8-Triazaspiro[4.5]decane Derivatives That Target the c Subunit of F1/FO-Adenosine Triphosphate (ATP) Synthase for the Treatment of Reperfusion Damage in Myocardial Infarction 141
2013 ESC guidelines on the management of stable coronary artery disease 139
Medical and interventional management of patients with severe thrombocytopenia undergoing percutaneous coronary intervention 138
KRIT1 deficiency promotes aortic endothelial dysfunction 137
Left Ventricular Lead Position Guided by Parametric Strain Echocardiography Improves Response to Cardiac Resynchronization Therapy 136
Predischarge screening for chronic obstructive pulmonary disease in patients with acute coronary syndrome and smoking history 135
European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions 135
Prolonged propionyl-L-carnitine pre-treatment of rabbit: biochemical, hemodynamic and electrophysiological effects on myocardium. 134
Management of coronary artery disease patients in Latvia compared with practice in Central-Eastern Europe and globally: Analysis of the CLARIFY registry 134
Tailored Medical and Interventional Therapy Against Recurrent Stent Thrombosis After Drug-Eluting Stenting 132
Fractional flow reserve evaluation and chronic kidney disease: Analysis from a multicenter Italian registry (the FREAK study) 132
Reperfusion Damage - A Story of Success, Failure, and Hope 132
A counseling program on nuisance bleeding improves quality of life in patients on dual antiplatelet therapy: A randomized controlled trial 132
Can we improve myocardial protection during ischaemic injury? 132
Factor XIII-A dynamics in acute myocardial infarction: a novel prognostic biomarker? 132
Cardiovascular complications of radiation therapy for thoracic malignancies: The role for non-invasive imaging for detection of cardiovascular disease 131
Individualized angiotensin-converting enzyme (ACE)-inhibitor therapy in stable coronary artery disease based on clinical and pharmacogenetic determinants: The PERindopril GENEtic (PERGENE) risk model 131
In Vitro Characterization of Circulating Endothelial Progenitor Cells Isolated from Patients with Acute Coronary Syndrome 129
Ticagrelor improves endothelial function by decreasing circulating Epidermal Growth Factor (EGF) 129
Coronary artery disease: Use of ACE inhibitors in stable CAD - What is the truth? 128
Antiplatelet Treatment Reduces All-Cause Mortality in COPD Patients: A Systematic Review and Meta-Analysis 128
Mutation Load of Multiple Ion Channel Gene Mutations in Brugada Syndrome 128
The in vitro effects of verbascoside on human platelet aggregation 127
Randomized, double-blind comparison of effects of abiciximab bolus only vs. on-label regimen on ex vivo inhibition of platelet aggregation in responders to clopidogrel undergoing coronary stenting 127
Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study 127
Abnormalities of left ventricular function in asymptomatic patients with systemic sclerosis using doppler measures of myocardial strain. 125
Grip strength predicts cardiac adverse events in patients with cardiac disorders: An individual patient pooled meta-analysis 125
A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals 124
Data on administration of cyclosporine, nicorandil, metoprolol on reperfusion related outcomes in ST-segment Elevation Myocardial Infarction treated with percutaneous coronary intervention 124
ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes 123
RESTING HEART RATE IN CARDIOVASCULAR DISEASE 122
Clinical benefit of drugs targeting mitochondrial function as an adjunct to reperfusion in ST-segment elevation myocardial infarction: A meta-analysis of randomized clinical trials 122
The assessment of scales of frailty and physical performance improves prediction of major adverse cardiac events in older adults with acute coronary syndrome 122
Is stunning an important component of preconditioning? 121
Cardiac troponin elevation predicts all-cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease: Systematic review and meta-analysis 121
Time course of human atrial natriuretic factor release during cardiopulmonary bypass in mitral valve and coronary artery diseased patients. 120
ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes (Am Journal of Cardiovasc Drugs (2011) 11:3 (189-98)) 120
Impact of a recent hospitalization on treatment and prognosis of ST-segment elevation myocardial infarction 120
Not just numbers, but years of science: Putting the ACE inhibitor—ARB meta-analyses into context 120
Prediction of absolute risk reduction of cardiovascular events with perindopril for individual patients with stable coronary artery disease - Results from EUROPA 120
Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis 120
Nutritional status and all-cause mortality in older adults with acute coronary syndrome 120
Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: A randomized multicenter trial 119
Appropriateness of Prescriptions of Recommended Treatments in Organisation for Economic Co-operation and Development Health Systems: Findings Based on the Long-Term Registry of the European Society of Cardiology on Heart Failure 119
A Clinical Case of Catecholaminergic Polymorphic Ventricular Tachycardia: The Clinical Suspicious and the Need of Genetics 119
Current role of echocardiography in cardiac resynchronization therapy 119
Quantitative Flow Ratio Identifies Nonculprit Coronary Lesions Requiring Revascularization in Patients with ST-Segment-Elevation Myocardial Infarction and Multivessel Disease 119
Sex-specific benefits of sirolimus-eluting stent on long-term outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Insights from the Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study trial 119
Long-Term Effect of Perindopril on Coronary Atherosclerosis Progression (from the PERindopril's Prospective Effect on Coronary aTherosclerosis by Angiography and IntraVascular Ultrasound Evaluation [PERSPECTIVE] Study) 118
High-dose BoluS TiRofibAn and Sirolimus eluting STEnt versus abiciximab and bare metal stent in acute MYocardial infarction (STRATEGY) study - Protocol design and demography of the first 100 patients 118
International cooperation in healthcare: Model of IRCCS Policlinico San Donato and Bambini Cardiopatici nel Mondo Association for congenital heart diseases 118
In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry 118
Endothelial dysfunction in acute and chronic coronary syndromes: evidence for a pathogenetic role of oxidative stress 118
SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials 118
Current views on anthracycline cardiotoxicity 118
EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot) 118
Reduction of oxidative stress by carvedilol: role in maintenance of ischaemic myocardium viability. 117
Angiotensin-converting enzyme inhibition in cardiovascular disease evidence with perindopril 117
Totale 16.194
Categoria #
all - tutte 273.188
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 4.298
Totale 277.486


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20206.826 0 0 0 0 0 1.426 1.121 1.276 1.024 1.199 488 292
2020/20218.376 681 744 515 930 363 913 316 1.061 254 1.119 996 484
2021/20227.070 323 777 577 273 413 357 359 366 296 505 753 2.071
2022/20236.078 715 190 226 668 982 900 219 634 840 60 397 247
2023/20243.481 359 433 210 120 238 490 152 206 77 160 153 883
2024/20254.576 303 307 1.107 466 1.429 964 0 0 0 0 0 0
Totale 58.310